“Sinovac Biotech” reveals the results of safety research. Inactivated vaccines for children only have 10 adverse reactions per 100,000 people in 14 countries around the world. Approved for emergency use in children aged 3 years and over is completed.
Bangkok, August 1, 2022 – Sinovac Biotech (Sinovac), a biopharmaceutical company that develops, researches and produces a vaccine against the COVID-19 virus. CoronaVac vaccine has revealed the latest research abroad on the safety and efficacy of inactivated vaccines. In the prevention of the COVID-19 virus from a study in a sample of children and youth who received the vaccine. Inactivated vaccines were found to have a low incidence of both short-term and long-term adverse effects. It can also increase antibody levels. in building immunity against the COVID-19 virus both the original species and the omikron species. After receiving all three doses of vaccine
In this regard, “Sinovac” is preparing to continue to study more vaccine research in children. The latter is certified for efficiency. of inactivated vaccines approved for use in children aged 3 years and over in 14 countries around the world. However, due to the epidemic situation of the COVID-19 virus Omicron strains with the BA.4–BA.5 mutation have seen a sharp increase in the number of infections since mid-June. According to the World Health Organization (WHO), the virus is the leading cause of the increase in cases in Europe and the United States. While different strains of the virus have been found in other countries such as India and Thailand. By the epidemic in this wave, the main risk group is schoolchildren. This is because schools across the country have resumed their semester and are ready to study on site again in May.
while the information from doctors who specialize in clinical virology Department of pediatrics in Thailand has released information that The spread of COVID-19 in this round, students will spread and spread the disease. The same is true for other respiratory diseases, such as influenza, which are often found to be very high during the school term or the rainy season. Students are more easily exposed to the virus when the semester starts. vaccinate that COVID-19 infection can be repeated And even if vaccinated, it can still be infected.
Vaccination will help prevent the severity of the disease after infection. But what is worrying is the children and youth groups. Because most children have just received their first dose of vaccination. and have not received a booster There are also some groups of children who have never been vaccinated against COVID-19 in any way. The FDA gives injections to children, including inactivated vaccines. for children aged 6 years and over and mRNA vaccine for children aged 5 years and older for inactivated vaccines. It is a vaccine technology developed to prevent various diseases. in children for a long time, such as the hepatitis A vaccine and influenza vaccines, etc.
Mr Liu Peicheng, senior director of Sinovac, said: “In the past, Sinovac Biotech has continuously conducted inactivated vaccine research studies. In terms of safety and efficacy in immunization against COVID-19 among children, both in Hong Kong and abroad to reassure parents The latest, in addition to the inactivated COVID-19 vaccine, will be approved for vaccination for adults in 60 countries around the world, and also approved for use in children aged 3 years and over in 14 countries. with at present More than 260 million doses of Sinovac’s inactivated vaccine have been distributed to children worldwide.”
Sinovac also released an interesting study on the incidence of post-vaccination side effects among children from Chile. Based on data from the Chilean Institute of Public Health (ISP) from the COVID-19 Immunization Assessment Report. In children and youth aged 3 years and over, the number of more than 6.9 million injections nationwide. during the period of the survey Post-vaccination adverse reactions were reported in all types of children, representing 0.01%, or 868 of the total number of vaccinations among children. which details the reported results for the adverse reactions Inactivated vaccines also found the lowest reported effect rate at 10.67 per 100,000 doses, followed by 15.35 per 100,000 doses of mRNA vaccine.
In addition to the safety of vaccines Chile has previously conducted a study on the efficacy of a lethal vaccine in children. by collecting data from actual usage It was found that the inactivated vaccine was 74.5% effective in preventing COVID-19 infection among children, reducing the hospitalization rate by 91% and reducing the emergency room admission rate by 93.8%. Omicron Inactivated vaccines were found to reduce hospital admission rates by 64.6% and reduce emergency room admission rates. Among children aged 3-5 years, 69%, which Sinovac Biotech itself has conducted research that provides consistent results. It was found that the level of immunity in the children’s sample increased after two doses of inactivated vaccination and more than 30-fold in the third dose. The increase in antibodies against COVID-10 was more than 90%. Liu summed it up.
reference
1. Han, Bihua, et al. “Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. “The Lancet Infectious Diseases 21.12 (2021):
1645-1653. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2821%2900319-4/fulltext
2. Wang, Lei, et al. “Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial.” https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4099431
3. Rafael Araos, Alejandro Jara, Eduardo Undurraga et al. Effectiveness of CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak, 15 March 2022, PREPRINT (Version 1) available at Research Square https://doi .org/10.21203/
rs.3.rs-1440357/v1
4. Jara, Alejandro, et al. “Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study.” (2022) . https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4035405
5. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4099431
6. Fourth Statistical Report “HAART associated with the administration of SARS-CoV-2 vaccines in Chile”. In the paediatric and adolescent population Period: 01
March 2021 to 26 February 2022. https://vigilancia.ispch.gob.cl/app/esavi (Last Access 25 May 2022)
7. https://ddc.moph.go.th/covid19-dashboard/
About Sinovac
Sinovac Biotech is a biopharmaceutical company. located in china Focus on research, development, production and trading of vaccines. that prevents infectious diseases in humans Sinovac products Covering the COVID-19 vaccine Enterovirus 71 Hepatitis A and B seasonal flu 23 strains of pneumococcus, H5N1 pandemic influenza (avian influenza), H1N1 influenza (swine flu), chickenpox, mumps and polio. approved for urgent use or conditionally marketed in Asia, Latin America, Africa and the Middle East. Healive® Hepatitis A Vaccine manufactured by the Company It was assessed for qualification testing by the World Health Organization in 2016. 2017 EV71 Vaccine
which is an innovation of Sinovac To prevent HFMD caused by EV71, it was commercialized in China in 2016. 2016 In 2009, Sinovac was the first company in the world to be approved for the H1N1 influenza vaccine. and has been distributed for use with the Chinese government’s vaccination program and vaccine collection. The company is the sole supplier of the H1N1 influenza vaccine to the Chinese government’s vaccine collection program. Sabin of the company approved for registration In addition, the company Several other types of vaccines are being developed, including combination vaccines. Sinovac mainly sells vaccines in China. and is studying opportunities for growth in the international market. The company is looking for distribution channels for its products in many countries other than China. for more information Please visit the website www.sinovac.com
For more information, please contact:
Public Relations Consultant: JC&CO Communications JC&CO COMMUNICATIONS
Napat Kanchanachai / 081-355-9221 / [email protected] Kanthika Kaiyarat / 061-224-6146 / [email protected]
LINE OFFICIAL: @jccothailand